Hidradenitis suppurativa (HS) is a chronic autoinflammatory condition affecting the skin, the genetic mechanisms of which are ...

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it ...

Affinia Therapeutics Inc. has obtained IND clearance from the FDA for AFTX-201, an investigational genetic medicine for the ...

The BioWorld Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow ...

Researchers at Tangram Therapeutics Inc. have presented preclinical safety and efficacy data for TGM-148 in a model of von Willebrand disease.

Another two biopharma companies priced IPOs on Nasdaq to raise a combined $350 million, becoming the fourth and fifth firms to debut on U.S. markets in 2026.

The melanin-concentrating hormone (MCH) is one of the most potent central stimulators of feeding and regulates energy balance. Therefore, agonists of the melanin-concentrating hormone MCH1 receptor ...

The U.K.’s main research funding agency is looking to put more public money into proof of concept and pre-seed funding of putative university spinouts, to make them more investible and improve ...

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in lipid nanoparticles.

D-glucosaminidase (O-GlcNAcase; OGA) inhibitors described as potentially useful for the treatment of cancer, metabolic diseases, Alzheimer’s disease and progressive supranuclear palsy.

Scientists at Ghent University have created a mouse model that incorporates human versions of the receptors that recognize the fragment crystallizable (Fc) region of immunoglobulin G (IgG), one of the ...

After keeping the faith when it failed in the Modify phase III trial in October 2021, Idorsia Ltd. now has a clear route to market for lucerastat, an oral therapy for Fabry disease.